Hormonal inhibition of AR signaling is the therapeutic choice for patients with adenocarcinomas, but unfortunately, the disease usually progresses as it becomes independent of exogenous AR induction, leading to castration-resistant prostate cancer (CRPC) with a worse prognosis. Here, AR is linked to adenocarcinoma.